Elucidation of mechanisms underlying the therapeutic effects of cordycepin on pulmonary hypertension, with a focus on cell senescence and gut microbiota - 09/01/26
, Katsuya Hirano aAbstract |
Introduction |
Pulmonary hypertension (PH) is a progressive cardiopulmonary disorder characterized by excessive pulmonary vascular remodeling and aberrant proliferation of pulmonary artery smooth muscle cells (PASMCs). Emerging evidence suggests that gut microbiota dysbiosis contributes to PH development. Cordycepin, a natural adenosine analogue derived from Cordyceps militaris , has demonstrated antiproliferative and microbiota-modulating properties; however, its mechanism of action in PH remains unclear.
Objective |
Elucidate the mechanisms underlying the therapeutic effects of cordycepin on PH, focusing on cellular senescence and gut microbiota.
Methods |
The effects of cordycepin on PH pathology were investigated by transcriptome analysis of PASMCs from patients, and metagenomic analysis of rodent PH models. Cellular senescence was analyzed in lung tissue from p16 Ink4a -Cre ERT2 reporter mice and in rat bone marrow-derived macrophages (BMDMs).
Results |
RNA sequencing analysis revealed activation of p53 signaling by cordycepin in PASMCs. Cordycepin suppressed CDK1 expression and TERT phosphorylation at threonine 249. It ameliorated vascular and cardiac remodeling in PH rat and mouse models. Cordycepin induced M1-like macrophage senescence in p16 Ink4a reporter mice lungs and rat BMDMs. Cordycepin significantly reshaped the gut microbiota, increasing beneficial genera (e.g. Alistipes and Acetatifactor ) and reducing proinflammatory taxa (e.g., Ruminococcus ), with modulating key metabolic pathways, including short-chain fatty acid, tryptophan, and vitamin K2 metabolism.
Conclusion |
Cordycepin exerts multi-target therapeutic effects in PH by inhibiting PASMC proliferation via the p53–CDK1/pTERT axis, modulating gut microbiota-linked immunometabolism and induces proinflammatory macrophage senescence. These findings support cordycepin as a promising candidate for PH therapies targeting the vascular, immune, and gut–lung axes.
Le texte complet de cet article est disponible en PDF.Graphical Abstract |
Highlights |
• | Cordycepin alleviates PH by improving vascular remodeling and microbiota balance. |
• | RNA-seq shows p53 pathway activation by cordycepin in PH-PASMCs. |
• | Cordycepin suppresses PASMC proliferation via the p53–CDK1–pTERT axis. |
• | Cordycepin reshapes gut microbiota to reduce inflammation in PH. |
• | Cordycepin induces senescence of pro-inflammatory macrophages. |
Abbreviations : α-SMA, CDK1, HR, HPAECs, HPAH;, IPAH, IL-6, MCT, MCTp, PA, PAH, PH, PASMCs, RdRP, RVID, RVWT, TERT;, Cord
Keywords : Pulmonary hypertension, p53, CDK1, TERT, p16, Microbiota
Plan
Vol 194
Article 118923- janvier 2026 Retour au numéro
Article précédent
- Metabolic alterations driven by PFKFB3 upregulation confer resistance to trastuzumab in HER2-positive breast cancer
- Roos Vincken, Samuel T. Pasco, Veronica Steri, Laura Bozal-Basterra, Wilfred F.J. van IJcken, Arkaitz Carracedo, Danny Huylebroeck, Mark M. Moasser, Ana Ruiz-Sáenz
- The binding of the salvianolic acid A to the citrullinating enzyme PADI4 as a potential treatment for cancer
- Laureano E. Carpio, María Gabriela Álvarez-Rodríguez, David Recio-Moreno, Felipe Hornos, Izabel Georgieva-Nikolova, Ana Camara-Artigas, Virginia Rejas, Miguel Vidal, Martina Palomino-Schätzlein, Camino de Juan Romero, José L. Neira
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?